XLO

Xilio Therapeutics (XLO)

About Xilio Therapeutics (XLO)

Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on the discovery and development of tumor-activated immuno-oncology therapies for the treatment of cancer. The firm uses its Geographically Precise Solutions (GPS) platform to develop tumor-activated molecules, including cytokines, antibodies and other biologics. The company was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.

Details

Daily high

$9.62

Daily low

$9.02

Price at open

$9.11

52 Week High

$12.74

52 Week Low

$6.47

Market cap

59.9M

Dividend yield

0.00%

Volume

34,315

Avg. volume

37,892

P/E ratio

-2.49

Xilio Therapeutics News